Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies

Jielin Xu, Kelly Regan-Fendt, Siyuan Deng, William E. Carson, Philip R.O. Payne, Fuhai Li

Research output: Contribution to journalConference article

1 Scopus citations

Abstract

The emergence of drug resistance to traditional chemotherapy and newer targeted therapies in cancer patients is a major clinical challenge. Reactivation of the same or compensatory signaling pathways is a common class of drug resistance mechanisms. Employing drug combinations that inhibit multiple modules of reactivated signaling pathways is a promising strategy to overcome and prevent the onset of drug resistance. However, with thousands of available FDA-approved and investigational compounds, it is infeasible to experimentally screen millions of possible drug combinations with limited resources. Therefore, computational approaches are needed to constrain the search space and prioritize synergistic drug combinations for preclinical studies. In this study, we propose a novel approach for predicting drug combinations through investigating potential effects of drug targets on disease signaling network. We first construct a disease signaling network by integrating gene expression data with disease-associated driver genes. Individual drugs that can partially perturb the disease signaling network are then selected based on a drug-disease network “impact matrix”, which is calculated using network diffusion distance from drug targets to signaling network elements. The selected drugs are subsequently clustered into communities (subgroups), which are proposed to share similar mechanisms of action. Finally, drug combinations are ranked according to maximal impact on signaling sub-networks from distinct mechanism-based communities. Our method is advantageous compared to other approaches in that it does not require large amounts drug dose response data, drug-induced “omics” profiles or clinical efficacy data, which are not often readily available. We validate our approach using a BRAF-mutant melanoma signaling network and combinatorial in vitro drug screening data, and report drug combinations with diverse mechanisms of action and opportunities for drug repositioning.

Original languageEnglish
Pages (from-to)92-103
Number of pages12
JournalPacific Symposium on Biocomputing
Volume0
Issue number212669
DOIs
StatePublished - Jan 1 2018
Event23rd Pacific Symposium on Biocomputing, PSB 2018 - Kohala Coast, United States
Duration: Jan 3 2018Jan 7 2018

Keywords

  • Drug combination
  • Drug repositioning
  • Network diffusion
  • Signaling network

Fingerprint Dive into the research topics of 'Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies'. Together they form a unique fingerprint.

  • Cite this